C90.32
BillableSolitary plasmacytoma in relapse
HCC Category Mapping
V28HCC 19 — Lymphoma and Other Cancers
0.105V24HCC 10 — Lymphoma and Other Cancers
0.675ESRDHCC 10 — Lymphoma and Other Cancers
0.000RxHCCHCC 16 — Multiple Myeloma and Plasma Cell Neoplasms
0.000What This Code Means
A single tumor made of plasma cells that has returned after a period of remission.
Coding Tips
- •Relapse means the cancer has recurred; ensure documentation supports this status rather than initial diagnosis
- •Distinguish between relapse and progression during ongoing treatment
Clinical Significance
Solitary plasmacytoma in relapse indicates recurrence of the bone lesion after achieving remission, which may occur at the original site or as a new solitary bone lesion. Relapse is a critical juncture as it significantly increases the likelihood of progression to systemic multiple myeloma. Comprehensive restaging is essential to determine whether the disease remains solitary or has evolved into multiple myeloma.
Documentation Requirements
- ✓Documentation must show evidence of recurrence after documented remission, with imaging confirming the relapsed lesion.
- ✓Complete restaging including bone marrow biopsy, skeletal survey or PET-CT, and serum and urine protein studies must be performed to exclude myeloma evolution.
- ✓New treatment plan and disease burden assessment must be recorded.
Commonly Confused Codes
C90.30 (solitary plasmacytoma not in remission) is for initial non-response.C90.31 (solitary plasmacytoma in remission) indicates no recurrence.C90.02 (multiple myeloma in relapse) should be used if restaging reveals systemic disease.C90.20 (extramedullary plasmacytoma) applies to soft tissue relapse.
Code Hierarchy
└C90Multiple myeloma and malignant plasma cell neoplasms└C90.3Solitary plasmacytoma└C90.32Solitary plasmacytoma in relapse
└C90.32Solitary plasmacytoma in relapse